Moderna takes another expansion step, snapping up Japanese mRNA company

4 January 2023
moderna-logo-large

Taking advantage of the vast cash pile generated by the success of its COVID-19 vaccine Spikevax, US mRNA therapeutics and vaccines specialist Moderna (Nasdaq: MRNA) today announced its first out-right acquisition since its launch in 2020.

Moderna revealed that it has reached an agreement to acquire Tokyo, Japan-based start-up OriCiro Genomics, a pioneer in cell-free DNA synthesis and amplification technologies, for $85 million.

"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, chief executive of Moderna, adding: "OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology